Pseudomyxoma peritonei
Methodology & AI Transparency ⓘ
Pseudomyxoma peritonei Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as C78.6, Pseudomyxoma peritonei falls under Cancer & Oncology management, where targeted/immunotherapy [Pseudomyxoma peritonei C78.6] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry C78.6: Pseudomyxoma peritonei is managed within Cancer & Oncology.
- 3 Typical cash cost range: Differential triage of Pseudomyxoma peritonei (C78.6) utilizes targeted/immunotherapy [Pseudomyxoma peritonei C78.6].
- 4 Top reported side effects / signs: Objective lab/clinical target for Pseudomyxoma peritonei: Comprehensive Metabolic & in Pseudomyxoma peritonei (C78.6: Organ Function Panel) (Preserved renal/hepatic clearance (C78.6)) and Pathology / Molecular in Pseudomyxoma peritonei (C78.6: Genomic Staging).
Ask our AI Specialists anything about Pseudomyxoma peritonei
What Is Pseudomyxoma peritonei?
Designated in federal medical registries as C78.6, Pseudomyxoma peritonei falls under Cancer & Oncology management, where targeted/immunotherapy [Pseudomyxoma peritonei C78.6] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Pseudomyxoma peritonei (ICD-10 C78.6) is driven by potential lymphatic or in Pseudomyxoma peritonei (C78.6: hematogenous dissemination if); specialists in Cancer, Oncology & Supportive Care monitor Pathology / Molecular in Pseudomyxoma peritonei (C78.6: Genomic Staging) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Pseudomyxoma peritonei (C78.6): persistent painless lump, in Pseudomyxoma peritonei (C78.6: non-healing ulcer/mole change,)
- • Secondary Pseudomyxoma peritonei clinical sign: unintended weight loss [Pseudomyxoma peritonei C78.6]
- • Symptom flares in Pseudomyxoma peritonei correlating with Comprehensive Metabolic & in Pseudomyxoma peritonei (C78.6: Organ Function Panel) deviation outside Preserved renal/hepatic clearance (C78.6)
- • Functional cancer & oncology impact requiring targeted/immunotherapy [Pseudomyxoma peritonei C78.6] evaluation (C78.6)
Pseudomyxoma peritonei Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C78.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Pseudomyxoma peritonei (C78.6: Organ Function Panel) | Preserved renal/hepatic clearance (C78.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Pseudomyxoma peritonei (C78.6: Genomic Staging) | Guideline-concordant surveillance (C78.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Pseudomyxoma peritonei (C78.6: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C78.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pseudomyxoma peritonei
Treatment selection for Pseudomyxoma peritonei depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pseudomyxoma peritonei)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid: What a 406-Participant Study Found There was no significant difference between treatments in secondary efficacy endpoints, reflecting a lack of clinical response. Leukemia research • 2024-05-15 • Phase III Randomized Trial | N = 406 | 93/100 | PMID 38499457 ↗ |
| Can This Approach Help? Inside the Latest Research on Discontinuation of the gold-standard blind, compared against a dummy pill XXL was a compared against a dummy pill (placebo) phase 3 evaluating cetuximab-radiotherapy and xevinapant (IAP inhibitor) in locally advanced squamous cell carcinoma of the head and neck, ineligible for cisplatin (Unfit). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2026-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41903611 ↗ |
| New Insights on Acute and Late Radiation-Related Toxicity After Treatment of Locally Advanced: What a 352-Participant Study Found IMRT was not associated with less radiation-related toxicity compared with 3D-CRT after TNT or CRT. International journal of radiation oncology, biology, physics • 2025-10-01 • Phase III Randomized Trial | N = 352 | 87/100 | PMID 40354950 ↗ |
| New Insights on Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer:: What a 268-Participant Study Found These findings support the use of durvalumab plus EP as first-line standard of care for ES-SCLC. Clinical lung cancer • 2025-12-15 • Phase III Randomized Trial | N = 268 | 87/100 | PMID 40887341 ↗ |
| Can This Approach Help? Inside the Latest Research on Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the BF-200 ALA showed significantly higher AK clearance rates on extremities, trunk, and neck than the vehicle and was well tolerated. Journal of the American Academy of Dermatology • 2021-12-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33744350 ↗ |
Pseudomyxoma peritonei Patient Community & “People Like Me” Threads
Filter Pseudomyxoma peritonei community threads and patient logs by age, biological sex, dosage, and treatment duration.